title: Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
abstract: OBJECTIVE
  Neoadjuvant chemotherapy is increasingly considered an effective treatment option for patients with gastric carcinoma. Aim of the study is to evaluate the prognostic significance of the pathological response and of known prognostic factors in a group of accurately staged locally advanced gastric cancer (LAGC) patients.
  
  
  METHODS
  Thirty-three patients with LAGC, staged by laparoscopy, underwent D2-gastrectomy after preoperative chemotherapy. Survival was calculated by Kaplan-Meier method and differences were assessed by the Log-rank and Breslow test. Multivariate analysis was performed using the Cox proportional hazard model in backward stepwise regression.
  
  
  RESULTS
  Curative resection (R0) was achieved in 81.8% of patients. A complete or subtotal pathological response was documented in 3 and 6%, respectively. Nineteen out of thirty-three (57.6%) patients were alive and 16 of them were free of relapse at last follow-up. Survival rates were 81, 67, and 59% at 12, 24, and 36 months, respectively. At univariate and multivariate analysis, only R0 resection was found to be an independent prognostic factor.
  
  
  CONCLUSIONS
  In the current study, R0 resection is the most important prognostic factor for resectable LAGC; according to our results we feel encouraged to consider neoadjuvant chemotherapy a promising modality for increasing the R0-percentage of gastric carcinoma patients who could benefit from a curative surgery.
authors.affiliation: Department of Surgery, Catholic University, Rome, Italy. rpersiani@rm.unicatt.it <rpersiani@rm.unicatt.it>
authors.forename: Roberto
authors.initials: R
authors.lastname: Persiani
authors.forename: Domenico
authors.initials: D
authors.lastname: D'Ugo
authors.forename: Stefano
authors.initials: S
authors.lastname: Rausei
authors.forename: Daniel
authors.initials: D
authors.lastname: Sermoneta
authors.forename: Carlo
authors.initials: C
authors.lastname: Barone
authors.forename: Carmelo
authors.initials: C
authors.lastname: Pozzo
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ricci
authors.forename: Giuseppe
authors.initials: G
authors.lastname: La Torre
authors.forename: Aurelio
authors.initials: A
authors.lastname: Picciocchi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy / Q000379:methods*; D006801:Humans; D010535:Laparoscopy; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011300:Preoperative Care; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
chemical_list: D015251:Epirubicin; D005047:Etoposide; D002945:Cisplatin; D005472:Fluorouracil